Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors

US9273064B2 · kind B2 · utility

Assignee

• Leo Pharma A/S · DK

Inventor

• Simon Feldbaek Nielsen · Rang Taché Est, DK

Key dates

• Filing date: Dec 30, 2014
• Grant date: Mar 1, 2016
• Expiry date: Dec 30, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the general formula Iwhereineach of m and n is independently 0 or 1;R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—;R3 is —CHF2, —CF3, —OCHF2, —OCF3, —SCHF2 or —SCF3;X is a bond, —CH2—, or —NH—;A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; andR4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy;or pharmaceutically acceptable salts, hydrates or solvates thereof,have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.